Natalizumab Antibodies
Also known as: NATAL ABS
Use
This test aids in the management of individuals receiving natalizumab therapy. Natalizumab is an immunosuppressive drug used to treat some chronic inflammatory conditions. Detecting antibodies to natalizumab can be important for evaluating treatment effectiveness and monitoring for drug-related adverse reactions such as the development of neutralizing antibodies which may diminish the efficacy of the treatment.
Special Instructions
Not provided.
Limitations
The test was developed and its performance characteristics were determined by Eurofins Viracor, but it has not been cleared or approved by the U.S. Food and Drug Administration. Potential limitations include false positives or negatives due to cross-reactivity or insufficient sensitivity to detect low antibody levels.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
Natalizumab Antibodies
Protein
LOINC Codes
- 58012-6 - Natalizumab Ab Ser Ql
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Allow blood to clot at room temperature for 30 minutes. Separate serum from cells within 1 hour.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 2 Weeks |
| Frozen | 2 Weeks |
Other tests from different labs that may be relevant